#USA #Denver #Salmonella #QuantiPath #GenoPATHx

QuantiPath's Expanded À La Carte Multiplex Options

QuantiPath, a leader in molecular diagnostics, has recently signed a new chapter in food safety with the unveiling of an expanded portfolio of testing options tailored specifically for the detection of Salmonella. This significant move, announced on January 15, 2026, marks the company's commitment to advancing pathogen detection technology and enhancing food safety practices.

Significant Portfolio Expansion

The new offerings include enhanced à la carte multiplex Salmonella primer and probe options, designed to provide laboratories with increased flexibility in designing and deploying testing assays. This innovation allows for a dramatic expansion in the number of available Salmonella serovar options, enabling customers to tailor their testing panels according to various needs, whether they be customer-based, regulatory, or investigative.

John LoPorto, CEO and President of QuantiPath, emphasized the importance of this product line expansion, stating, "This is our first product line expansion of 2026. We will be rolling out several others later this year, some based on customer requests while others will broaden the markets we serve.”

Non-Multiplex qPCR Testing Options

In addition to the expanded multiplex capabilities, QuantiPath is also introducing non-multiplex qPCR testing pathways. These new assays utilize SYBR® Green-based detection chemistry, which is well-known for its reliability and simplicity, particularly in non-multiplex workflows. This type of testing is designed for focused, single-target applications, meeting the diverse needs of laboratories whether they require a rapid deployment or a more straightforward testing method.

Dr. Elizabeth Krushinskie, VP-Poultry at QuantiPath, highlighted the practical benefits of these new testing pathways: "Because of the complex and often variable nature of Salmonella control programs from farm to fork, having the ability to identify and quantify specific serovars of interest at each step of the production system gives producers a more granular view of which interventions work and which don't. This ultimately saves time, money, and reduces risk.”

Meeting Diverse Laboratory Requirements

QuantiPath’s approach reflects a deep understanding of the varying requirements laboratories face, from high-throughput screening programs to focused investigations. By supporting both multiplex and non-multiplex testing strategies, they are empowering laboratories to adopt scalable molecular tools that seamlessly align with their specific operational demands.

The company’s flagship product, GenoPATHx, exemplifies its dedication to food safety testing. This innovative kit is the only rapid testing solution capable of identifying and quantifying multiple Salmonella serovars simultaneously, giving food industry stakeholders unprecedented insight into microbial contamination.

With a skilled team comprising geneticists, microbiologists, and seasoned industry professionals, QuantiPath is paving the way for enhanced data clarity and operational confidence in food safety. This expansion not only represents a significant step in the field but also reinforces QuantiPath's commitment to leading advancements in food safety diagnostics.

For more information about QuantiPath and its product offerings, visit www.QuantiPath.bio and stay tuned for updates on their LinkedIn page.

Conclusion

As QuantiPath progresses through 2026, the company’s ongoing product expansions signal their proactive approach to evolving the landscape of molecular diagnostics in food safety. With each new offering, they strive to provide tools that not only enhance safety but also support the demands of modern food production and distribution systems.